


Listing of Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application.

1.(Previously presented.) A compound of formula I:



wherein:

A is a moiety of formula II:



D is oxygen or sulfur;

E is a single bond, oxygen, sulfur, or NR³;

Ar¹ is a 5- or 6-membered aromatic heterocyclic ring having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar¹ is phenyl;

Ar² is a 5- or 6-membered aromatic heterocyclic ring having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar² is phenyl, or

Ar² is an 8- or 9-, or 10-membered fused aromatic carbocyclic ring or fused aromatic heterocyclic ring having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or an 8- or 9-, or 10-membered aromatic carbocyclic ring;

the rings Ar¹ and Ar² are substituted with 0, 1, 2 or 3 substituents selected from: halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, NO₂, CF₃, NR¹R², CH₂NR¹R², OR², CH₂OR² or CO₂R³;

R¹ and R² at each occurrence are independently selected from hydrogen, C₁₋₄alkyl, aryl, heteroaryl, C(O)R³, C(O)NHR³, CO₂R³ or SO₂R³, or

R¹ and R² in combination is -(CH₂)_jG(CH₂)_k- wherein G is oxygen, sulfur, NR³, or a bond;

a, b and c are each 1;

j is 2, 3 or 4;

k is 0, 1 or 2, and

R³ at each occurrence is independently selected from hydrogen, C₁₋₄alkyl, aryl, or heteroaryl;

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

2. (Original) A compound according to Claim 1, wherein D is oxygen.

3. (Original) A compound according to Claim 2, wherein E is a single bond.

4. (Original) A compound according to Claim 2, wherein E is oxygen or NR³.

5. (Canceled.)

6. (Original) A compound of Claim 1, wherein

Ar¹ is a 5- or 6-membered aromatic heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or

Ar¹ is phenyl,

or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

7. (Original) A compound according to Claim 6 wherein Ar¹ is a benzene ring, furan ring or thiophene ring.

8. (Original) A compound according to Claim 1, wherein

Ar² is a 5- or 6-membered aromatic heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or a phenyl,
or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

9. (Original) A compound according to Claim 8, wherein Ar² is a benzene ring, furan ring, thiophene ring, or pyridine ring.

10. (Original) A compound according to Claim 1, wherein

the -EAr² and the C(=D)A moieties on Ar¹ are positioned in a 1,3-relationship relative to each other;
or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

11. (Previously presented.) A compound according to Claim 1, wherein Ar¹ or Ar² is substituted with 0 or 1 substituents selected from: halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, NO₂, NR¹R², CH₂NR¹R², OR², CH₂OR², CO₂R³ or CF₃;
or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

12-13.(Canceled.)

14.(Previously presented.) A compound according to Claim 1, having the groups -EAr² and -C(=O)A, positioned in a 1,3-relationship relative to each other and wherein Ar² has 0 or 1 substituents selected from: halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, CN, NO₂, NR¹R², CH₂NR¹R², OR², CH₂OR², CO₂R³ or CF₃;
or a diastereoisomer, enantiomer or pharmaceutically-acceptable salt thereof.

15-18. (Canceled.)

19. (Previously presented.) A method of treatment of psychotic disorders, intellectual impairment disorders, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis which method comprises administering a therapeutically effective amount of a compound as defined in Claim 1.

20.(Previously presented) A pharmaceutical composition comprising a compound of formula I, as defined in claim 1, together with at least one pharmaceutically-acceptable excipient or diluent.

21-23. (Canceled.)